PBU The Pension Fund of Early Childhood & Youth Educators Invests $26.80 Million in Adaptive Biotechnologies Corporation $ADPT

PBU The Pension Fund of Early Childhood & Youth Educators acquired a new position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,650,303 shares of the company’s stock, valued at approximately $26,801,000. Adaptive Biotechnologies accounts for 1.0% of PBU The Pension Fund of Early Childhood & Youth Educators’ portfolio, making the stock its 11th biggest holding.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Allianz Asset Management GmbH boosted its position in Adaptive Biotechnologies by 305.8% in the 3rd quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock valued at $4,814,000 after buying an additional 242,474 shares during the last quarter. 1492 Capital Management LLC purchased a new position in Adaptive Biotechnologies in the 4th quarter valued at about $1,484,000. UBS Group AG boosted its position in Adaptive Biotechnologies by 101.6% in the 4th quarter. UBS Group AG now owns 511,927 shares of the company’s stock valued at $8,314,000 after buying an additional 257,947 shares during the last quarter. Affinity Wealth Management LLC purchased a new position in Adaptive Biotechnologies in the 3rd quarter valued at about $4,541,000. Finally, Jupiter Asset Management Ltd. boosted its position in Adaptive Biotechnologies by 33.8% in the 4th quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock valued at $5,892,000 after buying an additional 91,683 shares during the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Stock Down 6.5%

Shares of NASDAQ ADPT opened at $16.90 on Friday. The firm’s 50-day moving average price is $14.17 and its two-hundred day moving average price is $15.61. Adaptive Biotechnologies Corporation has a 52-week low of $9.90 and a 52-week high of $20.76. The stock has a market capitalization of $2.70 billion, a P/E ratio of -51.21 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The firm had revenue of $70.87 million for the quarter, compared to analysts’ expectations of $61.03 million. During the same quarter last year, the company posted ($0.20) earnings per share. Adaptive Biotechnologies’s revenue was up 35.1% on a year-over-year basis. As a group, equities research analysts expect that Adaptive Biotechnologies Corporation will post -0.48 earnings per share for the current year.

Insider Transactions at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Sharon Benzeno sold 63,103 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total value of $831,066.51. Following the transaction, the insider owned 272,751 shares of the company’s stock, valued at $3,592,130.67. This trade represents a 18.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Susan Bobulsky sold 41,338 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total transaction of $544,421.46. Following the completion of the transaction, the insider directly owned 427,775 shares in the company, valued at $5,633,796.75. This represents a 8.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,771,096 shares of company stock valued at $23,926,217 over the last ninety days. Insiders own 5.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. TD Cowen upped their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. BTIG Research reissued a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Piper Sandler set a $21.00 price objective on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.57.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.